Navigation Links
Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Date:10/23/2008

New drug is company's third to enter human trials in 2 years

DURHAM, N.C., Oct. 23 /PRNewswire/ -- Addrenex Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved its Investigational New Drug Application (IND) for ADX415, a novel hypertension drug. With the approval, Addrenex has launched a phase 2 clinical trial to study ADX415 as a targeted therapy for hypertension.

The phase 2 trial is a multicenter, double-blind, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist specific to alpha-2 receptors.

ADX415 is the company's third drug to receive IND approval and enter human trials in a 2-year period, continuing the rapid pace of drug development at Addrenex. ADX415 was identified from an extensive library of alpha-2 adrenergic compounds that Addrenex licensed from the University of Nebraska Medical Center and that originated from Procter & Gamble Pharmaceuticals.

The scientific focus of Addrenex is the treatment of medical conditions that arise from an overactive or improperly regulated adrenergic system, a group of hormones produced by the adrenal glands that regulates diverse physiologic functions such as blood pressure, heart rate and response to stress.

"Numerous medical conditions arise from an overactive adrenergic nervous system, yet few drugs are available that specifically target this complex pathway," said Moise Khayrallah, cofounder and chief executive officer of Addrenex. "We built our company to address a wide range of conditions whose symptoms are not fully managed by drugs currently on the market. Our scientific team continues to identify and analyze alpha-2 compounds that could potentially address the unmet needs of patients across a wide range of conditions."

The company's first two drug candidates are Clonicel to treat attention deficit hyperactivity disorder (ADHD) and CloniBID to treat hypertension. Clonicel is currently in phase 3 trials, and a new drug application has been filed for CloniBID with FDA review expected by the end of the year. Commercial rights to both drugs, and to ADX415, have been granted to Atlanta-based Sciele Pharma, a Shionogi Company.

About Addrenex Pharmaceuticals, Inc.

Addrenex Pharmaceuticals is a focused specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, N.C., on the edge of Research Triangle Park. The company was formed in 2006 by a practicing physician and a drug development expert with the mission to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraines and postmenopausal symptoms. Addrenex will use the knowledge and experience gained from developing CloniBID and Clonicel as the foundation for additional discovery and development in the area of adrenergic regulation.


'/>"/>
SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Nev. , May 24, 2016  Diana Russell ... "eats" her organs from the inside out.  This disease ... completely dependent on her children and grandchildren to leave ... her wheelchair, Diana,s family cannot haul the wheelchair.  So ... in the car, and Diana is left to wait ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... First Choice Emergency Room , the ... Tat Nguyen, as the Medical Director of its new DeSoto facility. , “We ... new DeSoto location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching a ... patented refillable hanging wipe dispenser. The campaign kick-off video is located via this link ... 25, 2016. The goal is to raise $1,000 per day for a total of ...
(Date:5/24/2016)... Michigan (PRWEB) , ... May 24, 2016 , ... ... Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified Nurse Midwife ... Grand Valley State University and then went on to complete her masters degree ...
(Date:5/24/2016)... ... 2016 , ... Educational opportunities, and therefore life chances, have ... providing richer opportunities. Recognizing the key role of housing in this system, equity-minded ... choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused policies. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed ... stem cell therapy technology, protocols and patient results as have been achieved with ... a more accessible standard of care for patients worldwide. , As the Medical Advisory ...
Breaking Medicine News(10 mins):